Olivier Rixe, MD, PhD, is an internationally recognized medical oncologist in the field of developmental therapeutics. Dr. Rixe has received numerous awards, which include the Merit Order (Ordre National du Merite) for cancer research from the President of France, Jacques Chirac.
While working as an oncologist, he has had nearly 150 publications in peer-reviewed journals. He has held a senior position in academia for the past 15 years where he has conducted clinical trials in patients with resistant tumors, including many translational studies.
Active in numerous drug trials, Dr. Rixe has been involved in the early phases of development for FDA approved agents, such as oxaliplatin, camptothecins, and taxanes, as well as targeted therapies including the antiangiogenic compounds sunitinib, axitinib and VEGF-trap.
Dr. Rixe has been a leader in Europe in the conduction of clinical trials in patients with numerous malignancies. He was also one of the early investigators who saw the value and promise of oxaliplatin and helped in its develop. He not only tested this drug in the clinical setting, but also in the laboratory, having conducted basic scientific studies at the National Institutes of Health (NIH) in Bethesda, MD. Oxaliplatin eventually became the cornerstone of colorectal cancer therapy.
Dr. Rixe received his medical degree from the Pierre and Marie Curie University of Paris in 1993, and completed 4 years of training in medical oncology and internal medicine in Paris. In 1992 he joined the National Cancer Institute's (NCI) Medical Oncology Branch, where he worked for one year. Following his training at the NCI, Dr. Rixe returned to France where he received his Ph.D. from the University Paris 7 in Paris, France. He served as a senior medical oncologist at Pitie-Salpetriere Hospital in Paris, and then in the Phase 1 Unit at Gustave Roussy Institute in Villejuif, France. Dr. Rixe was appointed Professor of Medical Oncology in 2003 at Pierre and Marie Curie University (Paris 6). In 2008, Dr. Rixe joined the Medicine Oncology Branch at the NCI in Bethesda, MD as a staff clinician.
In 2009, Dr. Rixe came to the University of Cincinnati (UC) as a Professor of Medicine and the John and Gladys Strauss Chair in cancer research and assumed the position of both Director of the Experimental Therapeutics Program and Research Director of the UC Brain Tumor Center.
Dr. Rixe recently joined GHSU Cancer Center and leads the Experimental Therapeutics Program and the multi-Disciplinary Neuro-Oncology group.